Back

PTPN11 Mutation Clonal Hierarchy in Acute Myeloid Leukemia

Fobare, S.; Sharpe, C.; Quinn, K.; Bryant, K.; Miles, L. A.; Bowman, R. L.; Cheney, C.; Furby, C.; Long, M.; Fyock, K.; Wronowski, B.; Lerma, J. R.; Mullaney, A.; Mrozek, K.; Nicolet, D.; Sesterhenn, T.; Johnstone, M. E.; Rai, S. N.; Pasare, C.; Zimmermann, N.; Carroll, A. J.; Stone, R. M.; Wang, E. S.; Kolitz, J. E.; Powell, B. L.; Perentesis, J. P.; Eisfeld, A.-K.; Hertlein, E.; Byrd, J. C.

2024-09-20 cancer biology
10.1101/2024.09.18.612239 bioRxiv
Show abstract

Mutations in protein tyrosine phosphatase non-receptor type 11 (PTPN11) have been considered late acquired mutations in acute myeloid leukemia (AML) development. To interrogate the ontogeny of PTPN11 mutations, we utilized single-cell DNA sequencing and identified that PTPN11 mutations can occur as initiating events in some AML patients when accompanied by strong oncogenic drivers, commonly NPM1 mutations. The co-driver role of PTPN11 mutations was confirmed in a novel murine model that exhibits an AML phenotype with early expansion of a diverse set of variably differentiated myeloid cells that engrafted into immunodeficient and immunocompetent mice. This immune diversity was reconstituted from early precursor cells when engrafted into immunodeficient mice. Moreover, immune diversity was also observed in the blast component of patient samples with NPM1 and PTPN11 mutations, providing novel antigen targets for immune based approaches in this subset of AML that is resistant to multiple targeted therapies.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.